CJC-1295 vs Follistatin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Follistatin

Follistatin is a glycoprotein that inhibits myostatin, the protein responsible for limiting muscle growth. By blocking myostatin, follistatin can theoretically allow for increased muscle development beyond natural limits.

Full details →

Side-by-Side Comparison

Aspect	CJC-1295	Follistatin
Dose Range	1 mg–2 mg	50 mcg–100 mcg
Frequency	Less than daily	1x daily
Cycle Length	8–12 weeks	2–4 weeks
Route	subcutaneous	subcutaneous
Mechanism	CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.	Binds to and neutralizes myostatin and activin, both of which are negative regulators of muscle mass. This removes the natural brake on muscle growth, allowing for enhanced hypertrophy.
Typical Dosage	CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.	Research protocols typically use 100-300mcg daily, though optimal dosing is not well established. Gene therapy approaches have also been studied.
Administration	Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.	Subcutaneous injection. Different isoforms exist (FS344, FS315) with varying properties. Requires careful sourcing due to complexity.
Side Effects	Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.	Limited human data. Theoretical concerns about effects on other organs where activin signaling is important.
Best For	Muscle Growth Fat Loss Sleep Quality	Muscle Growth